论文部分内容阅读
目的:探讨细胞分裂周期蛋白6(CDC6)在肝细胞癌(HCC)中的表达及其临床意义。方法:分别用q RT-PCR、Western blot和免疫组化法检测85例手术切除的HCC及对应癌旁组织标本中CDC6 m RNA及蛋白的表达,分析CDC6的表达与HCC患者临床病理因素及预后关系。结果:HCC组织中CDC6的m RNA与蛋白表达水平均高于对应癌旁组织,q RT-PCR结果定量分析显示差异有统计学意义(P<0.05);CDC6表达与肿瘤大小、临床分期、分化程度及卫星结节有关(均P<0.05);CDC6高表达的患者无瘤生存时间和总生存时间均低于CDC6低表达患者(均P<0.05);单因素与多因素分析显示,CDC6是影响HCC患者无瘤生存率(HR=1.089,95%CI=0.986~1.186,P=0.033)及总生存率(HR=2.441,95%CI=1.128~3.652,P=0.012)的独立危险因子。结论:CDC6在HCC组织中高表达并与恶性临床病理特征及不良预后密切相关,CDC6可能参与HCC发生及进展,并可作为判断肿瘤复发及预后评价的重要指标。
Objective: To investigate the expression of cyclin 6 (CDC6) in hepatocellular carcinoma (HCC) and its clinical significance. Methods: The expression of CDC6 mRNA and protein in 85 cases of resected HCC and adjacent noncancerous tissues was detected by q RT-PCR, Western blot and immunohistochemistry. The expression of CDC6 and the clinicopathological factors and prognosis of HCC relationship. Results: The mRNA and protein expressions of CDC6 in HCC tissues were higher than those in corresponding adjacent tissues. The quantitative RT-PCR results showed that the difference was statistically significant (P <0.05). The expression of CDC6 correlated with tumor size, clinical stage, differentiation (All P <0.05); CDC6 overexpression in patients with CDC6 low expression-free survival time and survival time were lower (all P <0.05); univariate and multivariate analysis showed that CDC6 was (HR = 1.089, 95% CI = 0.986-1.186, P = 0.033) and overall survival (HR = 2.441, 95% CI = 1.128-3.652, P = 0.012) Conclusion: CDC6 is highly expressed in HCC tissues and is closely related to the clinicopathological features and adverse prognosis. CDC6 may be involved in the occurrence and progression of HCC, which may be used as an important index to evaluate tumor recurrence and prognosis.